Report Categories
View AllRecent Articles
View All
ANVS Annovis Bio shares drop 387 after Q4 2025 wider loss misses analyst estimates by 114
PCSA Processa Pharmaceuticals posts worsethanexpected Q4 2025 EPS results that miss estimates by 68 percent as shares edge 033 percent lower
IDN Intellicheck posts massive Q4 2025 EPS beat but shares sink 694 percent in todays trading